Sera Prognostics, Inc. (SERA) 10-Year Financial Performance & Capital Metrics

SERA • • Industrial / General

HealthcareDiagnostics & ResearchMolecular Diagnostics & Genetic TestingReproductive & Prenatal Genetics

AboutSera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Show more

Revenue $77K -74.8%
EBITDA -$36M +8.0%
Net Income -$33M +9.2%
EPS (Diluted) -0.99 +14.7%
Gross Margin -6.49% -120.7%
EBITDA Margin -46496.1% -265.6%
Operating Margin -47577.92% -265.6%
Net Margin -42724.68% -260.7%
ROE -55.78% -30.1%
ROIC -48.74% -14.3%
Debt/Equity 0.02 -33.6%
Interest Coverage -1308.39 -80.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 81 (top 19%)
✓Strong 5Y sales CAGR of 16.4%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y16.42%

3Y-2.08%

TTM1.06%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-1.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM22.22%

ROCE

10Y Avg-77.23%

5Y Avg-73.57%

3Y Avg-48.72%

Latest-61.67%

Peer Comparison

Reproductive & Prenatal Genetics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SERASera Prognostics, Inc.	132.45M	3.52	-3.56	-74.84%	-343.43%	-39.7%		0.02
NTRANatera, Inc.	33.52B	240.34	-157.09	56.75%	-14.61%	-24.69%	0.21%	0.16

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	36K	25K	82K	268K	306K	77K
Revenue Growth %	-	-0.31%	2.28%	2.27%	0.14%	-0.75%
Cost of Goods Sold+	18K	11K	37K	193K	210K	82K
COGS % of Revenue	0.5%	0.44%	0.45%	0.72%	0.69%	1.06%
Gross Profit+	18K	14K	45K	75K	96K	-5K
Gross Margin %	0.5%	0.56%	0.55%	0.28%	0.31%	-0.06%
Gross Profit Growth %	-	-0.22%	2.21%	0.67%	0.28%	-1.05%
Operating Expenses+	16.59M	17.98M	35.44M	45.73M	39.92M	36.63M
OpEx % of Revenue	460.94%	719.4%	432.2%	170.62%	130.45%	475.71%
Selling, General & Admin	7.24M	10.2M	24.42M	31.48M	24.69M	21.9M
SG&A % of Revenue	201.14%	408.12%	297.82%	117.47%	80.69%	284.42%
Research & Development	9.35M	7.78M	11.02M	14.24M	15.22M	14.73M
R&D % of Revenue	259.81%	311.28%	134.38%	53.15%	49.75%	191.3%
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-16.58M	-17.97M	-35.4M	-45.65M	-39.82M	-36.63M
Operating Margin %	-460.44%	-718.84%	-431.65%	-170.34%	-130.13%	-475.78%
Operating Income Growth %	-	-0.08%	-0.97%	-0.29%	0.13%	0.08%
EBITDA+	-15.63M	-17.08M	-34.74M	-44.9M	-38.92M	-35.8M
EBITDA Margin %	-434.17%	-683.04%	-423.61%	-167.52%	-127.19%	-464.96%
EBITDA Growth %	-	-0.09%	-1.03%	-0.29%	0.13%	0.08%
D&A (Non-Cash Add-back)	946K	895K	659K	756K	900K	833K
EBIT	-14.55M	-18.01M	-34.26M	-44.13M	-36.19M	-32.87M
Net Interest Income+	-1.91M	-1.8M	-601K	395K	1.58M	2.72M
Interest Income	64K	42K	145K	456K	1.64M	2.75M
Interest Expense	1.97M	1.84M	746K	61K	55K	28K
Other Income/Expense	55K	-1.88M	386K	1.47M	3.58M	3.74M
Pretax Income+	-16.52M	-19.85M	-35.01M	-44.19M	-36.24M	-32.9M
Pretax Margin %	-458.92%	-793.92%	-426.94%	-164.87%	-118.44%	-427.25%
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-16.52M	-19.85M	-35.01M	-44.19M	-36.24M	-32.9M
Net Margin %	-458.92%	-793.92%	-426.94%	-164.87%	-118.44%	-427.25%
Net Income Growth %	-	-0.2%	-0.76%	-0.26%	0.18%	0.09%
Net Income (Continuing)	-16.52M	-19.85M	-35.01M	-44.19M	-36.24M	-32.9M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-1.13	-1.19	-1.18	-1.43	-1.16	-0.99
EPS Growth %	-	-0.05%	0.01%	-0.21%	0.19%	0.15%
EPS (Basic)	-1.13	-1.19	-1.18	-1.43	-1.16	-0.99
Diluted Shares Outstanding	18.11M	18.11M	30.77M	30.94M	31.2M	33.16M
Basic Shares Outstanding	18.11M	18.11M	30.77M	30.94M	31.2M	33.16M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	21.55M	13.73M	110.25M	90.13M	61.34M	47.6M
Cash & Short-Term Investments	21.39M	13.53M	105.11M	82.7M	49.08M	46.24M
Cash Only	21.39M	13.53M	58.93M	29.88M	3.88M	4.04M
Short-Term Investments	0	0	46.18M	52.83M	45.2M	42.19M
Accounts Receivable	1K	2K	3.14M	6.11M	11.47M	34K
Days Sales Outstanding	10.14	29.2	13.99K	8.33K	13.68K	161.17
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	1.31M	795K	19K
Total Non-Current Assets+	1.71M	1.06M	36.78M	26.2M	34.1M	24.98M
Property, Plant & Equipment	1.64M	965K	1.77M	3.06M	3.18M	1.85M
Fixed Asset Turnover	0.02x	0.03x	0.05x	0.09x	0.10x	0.04x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	1.03M
Long-Term Investments	0	0	34.85M	21.33M	30.84M	21.97M
Other Non-Current Assets	72K	98K	157K	1.82M	77K	124K
Total Assets+	23.26M	14.8M	147.03M	116.33M	95.44M	72.58M
Asset Turnover	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x
Asset Growth %	-	-0.36%	8.94%	-0.21%	-0.18%	-0.24%
Total Current Liabilities+	5.9M	11.24M	8.41M	15.54M	24.44M	24.77M
Accounts Payable	748K	441K	1.2M	1.55M	1.05M	1.97M
Days Payables Outstanding	15.17K	14.63K	11.81K	2.93K	1.82K	8.76K
Short-Term Debt	3.67M	8.03M	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	1000K	1000K	0
Other Current Liabilities	294K	321K	3.56M	1.07M	926K	20.52M
Current Ratio	3.65x	1.22x	13.11x	5.80x	2.51x	1.92x
Quick Ratio	3.65x	1.22x	13.11x	5.80x	2.51x	1.92x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	6.4M	614K	54K	1.85M	840K	2K
Long-Term Debt	5.44M	348K	0	0	0	0
Capital Lease Obligations	134K	127K	54K	1.85M	840K	2K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	823K	139K	0	0	0	0
Total Liabilities	12.3M	11.86M	8.46M	17.39M	25.28M	24.77M
Total Debt+	9.31M	8.57M	128K	2.83M	1.86M	840K
Net Debt	-12.07M	-4.96M	-58.8M	-27.05M	-2.02M	-3.2M
Debt / Equity	0.85x	2.92x	0.00x	0.03x	0.03x	0.02x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-8.41x	-9.77x	-47.45x	-748.39x	-724.02x	-1308.39x
Total Equity+	10.96M	2.94M	138.56M	98.94M	70.16M	47.8M
Equity Growth %	-	-0.73%	46.13%	-0.29%	-0.29%	-0.32%
Book Value per Share	0.61	0.16	4.50	3.20	2.25	1.44
Total Shareholders' Equity	10.96M	2.94M	138.56M	98.94M	70.16M	47.8M
Common Stock	0	0	3K	3K	3K	3K
Retained Earnings	-111.61M	-131.46M	-166.47M	-210.65M	-246.9M	-279.79M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-183K	-981K	-15K	60K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19.32M	-16.87M	-31.64M	-34.61M	-27.19M	-14.19M
Operating CF Margin %	-536.78%	-674.72%	-385.8%	-129.14%	-88.85%	-184.27%
Operating CF Growth %	-	0.13%	-0.88%	-0.09%	0.21%	0.48%
Net Income	-16.52M	-19.85M	-35.01M	-44.19M	-36.24M	-32.9M
Depreciation & Amortization	946K	895K	659K	756K	900K	833K
Stock-Based Compensation	438K	726K	3.13M	5.05M	5.27M	7.01M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	-541K	1.67M	-372K	213K	-638K	-412K
Working Capital Changes	-3.65M	-311K	-44K	3.55M	3.52M	11.28M
Change in Receivables	6K	-2K	-3.14M	-2.97M	-5.36M	11.42M
Change in Inventory	0	0	0	0	0	0
Change in Payables	-534K	-307K	603K	352K	-442K	455K
Cash from Investing+	-6K	-149K	-82.56M	5.55M	438K	11.74M
Capital Expenditures	-109K	-149K	-1.3M	-791K	-128K	-56K
CapEx % of Revenue	3.03%	5.96%	15.9%	2.95%	0.42%	0.73%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	103K	0	0	16K	311K	-1.04M
Cash from Financing+	33.05M	9.16M	159.59M	5K	752K	2.61M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	15K	176K	1.66M	308K	1.22M	3.05M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-19.43M	-17.02M	-32.94M	-35.4M	-27.32M	-15.29M
FCF Margin %	-539.81%	-680.68%	-401.71%	-132.09%	-89.27%	-198.57%
FCF Growth %	-	0.12%	-0.94%	-0.07%	0.23%	0.44%
FCF per Share	-1.07	-0.94	-1.07	-1.14	-0.88	-0.46
FCF Conversion (FCF/Net Income)	1.17x	0.85x	0.90x	0.78x	0.75x	0.43x
Interest Paid	463K	250K	1.19M	48K	55K	28K
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-150.79%	-285.66%	-49.48%	-37.21%	-42.86%	-55.78%
Return on Invested Capital (ROIC)	-	-	-68.29%	-45.15%	-42.66%	-48.74%
Gross Margin	50%	56%	54.88%	27.99%	31.37%	-6.49%
Net Margin	-45891.67%	-79392%	-42693.9%	-16487.31%	-11843.79%	-42724.68%
Debt / Equity	0.85x	2.92x	0.00x	0.03x	0.03x	0.02x
Interest Coverage	-8.41x	-9.77x	-47.45x	-748.39x	-724.02x	-1308.39x
FCF Conversion	1.17x	0.85x	0.90x	0.78x	0.75x	0.43x
Revenue Growth	-	-30.56%	228%	226.83%	14.18%	-74.84%

Frequently Asked Questions

Growth & Financials

Sera Prognostics, Inc. (SERA) reported $0.1M in revenue for fiscal year 2024. This represents a 164% increase from $0.0M in 2019.

Sera Prognostics, Inc. (SERA) saw revenue decline by 74.8% over the past year.

Sera Prognostics, Inc. (SERA) reported a net loss of $32.6M for fiscal year 2024.

Dividend & Returns

Sera Prognostics, Inc. (SERA) has a return on equity (ROE) of -55.8%. Negative ROE indicates the company is unprofitable.

Sera Prognostics, Inc. (SERA) had negative free cash flow of $26.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener